Towards an improved investment approach for an effective response to HIV/AIDS

Substantial changes are needed to achieve a more targeted and strategic approach to investment in the response to the HIV/AIDS epidemic that will yield long-term dividends. Until now, advocacy for resources has been done on the basis of a commodity approach that encouraged scaling up of numerous strategies in parallel, irrespective of their relative effects. We propose a strategic investment framework that is intended to support better management of national and international HIV/AIDS responses than exists with the present system. Our framework incorporates major efficiency gains through community mobilisation, synergies between programme elements, and benefits of the extension of antiretroviral therapy for prevention of HIV transmission. It proposes three categories of investment, consisting of six basic programmatic activities, interventions that create an enabling environment to achieve maximum effectiveness, and programmatic efforts in other health and development sectors related to HIV/AIDS. The yearly cost of achievement of universal access to HIV prevention, treatment, care, and support by 2015 is estimated at no less than US$22 billion. Implementation of the new investment framework would avert 12·2 million new HIV infections and 7·4 million deaths from AIDS between 2011 and 2020 compared with continuation of present approaches, and result in 29·4 million life-years gained. The framework is cost effective at $1060 per life-year gained, and the additional investment proposed would be largely offset from savings in treatment costs alone.

[1]  Malaria.  The Global Fund 2010 : Innovation and impact , 2010 .

[2]  T. Hallett,et al.  Declines in HIV prevalence can be associated with changing sexual behaviour in Uganda, urban Kenya, Zimbabwe, and urban Haiti , 2006, Sexually Transmitted Infections.

[3]  Crime.,et al.  WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users.. , 2009 .

[4]  Constance A Nyamukapa,et al.  HIV Decline Associated with Behavior Change in Eastern Zimbabwe , 2006, Science.

[5]  T. Hallett,et al.  HIV and risk environment for injecting drug users: the past, present, and future , 2010, The Lancet.

[6]  A. Wensing,et al.  Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. , 2010, The Lancet. Infectious diseases.

[7]  Claire Glenton,et al.  Lay health workers in primary and community health care for maternal and child health and the management of infectious diseases. , 2010, The Cochrane database of systematic reviews.

[8]  M. Loevinsohn,et al.  HIV / AIDS food security and rural livelihoods: understanding and responding. , 2003 .

[9]  L. Myer,et al.  Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  R. Hayes,et al.  HIV prevention research: taking stock and the way forward , 2010, AIDS.

[11]  C. Watts,et al.  Eff ect of a structural intervention for the prevention of intimate-partner violence and HIV in rural South Africa : a cluster randomised trial , 2006 .

[12]  David P. Wilson,et al.  Kenya - HIV prevention response and modes of transmission analysis , 2009 .

[13]  C. Watts,et al.  Resource Needs for HIV/AIDS , 2001, Science.

[14]  J. Ndinya-Achola.  Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, Williams CF, Campbell RT, Ndinya-Achola JO.Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial.Lancet. 2007 Feb 24;369(9562):643-56. , 2007 .

[15]  S. Karim,et al.  HIV prevention transformed: the new prevention research agenda , 2011, The Lancet.

[16]  L. Dandona,et al.  HIV prevention costs and program scale: data from the PANCEA project in five low and middle-income countries , 2007, BMC Health Services Research.

[17]  Linda Richter,et al.  Community-based intervention to increase HIV testing and case detection in people aged 16-32 years in Tanzania, Zimbabwe, and Thailand (NIMH Project Accept, HPTN 043): a randomised study. , 2011, The Lancet. Infectious diseases.

[18]  L. Myer,et al.  Antiretroviral Therapy and TB Notification Rates in a High HIV Prevalence South African Community , 2011, Journal of acquired immune deficiency syndromes.

[19]  T. Ellerbrock,et al.  The cost of providing comprehensive HIV treatment in PEPFAR-supported programs , 2011, AIDS.

[20]  S Peterson,et al.  Barriers to use of antiretroviral drugs in Rakai district of Uganda. , 2010, African health sciences.

[21]  J. Mellors,et al.  Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy , 2008, Proceedings of the National Academy of Sciences.

[22]  Connie Celum,et al.  Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis , 2010, The Lancet.

[23]  L. Mofenson.  Prevention in neglected subpopulations: prevention of mother-to-child transmission of HIV infection. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  C. Watts,et al.  Effect of a structural intervention for the prevention of intimate-partner violence and HIV in rural South Africa: a cluster randomised trial , 2006, The Lancet.

[25]  L. Myer,et al.  Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control , 2006, AIDS.

[26]  R. Atun,et al.  Integration of targeted health interventions into health systems: a conceptual framework for analysis. , 2010, Health policy and planning.

[27]  Tim Evans,et al.  An assessment of interactions between global health initiatives and country health systems , 2009, The Lancet.

[28]  C. Watts,et al.  AIDS. Resource needs for HIV/AIDS. , 2001, Science.

[29]  Brian G. Williams,et al.  Antiretroviral Drugs for Tuberculosis Control in the Era of HIV/AIDS , 2003, Science.

[30]  S. Usdin.  Presenting the evidence for Social and Behavioural Communication , 2010 .

[31]  B. Pauly,et al.  Needle exchange as a safe haven in an unsafe world. , 2011, Drug and alcohol review.

[32]  Stephen Moses,et al.  Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial , 2007, The Lancet.

[33]  C. Ferreyra,et al.  Incidence of Tuberculosis in HIV-Infected Patients Before and After Starting Combined Antiretroviral Therapy in 8 Sub-Saharan African HIV Programs , 2011, Journal of acquired immune deficiency syndromes.

[34]  C. Dye,et al.  Antiretroviral therapy for tuberculosis control in nine African countries , 2010, Proceedings of the National Academy of Sciences.

[35]  Emmanuel Lagarde,et al.  Randomized, Controlled Intervention Trial of Male Circumcision for Reduction of HIV Infection Risk: The ANRS 1265 Trial , 2005, PLoS medicine.

[36]  R. Crosby,et al.  A review of STD/HIV preventive interventions for adolescents: sustaining effects using an ecological approach. , 2007, Journal of pediatric psychology.

[37]  A. Hardon,et al.  HIV-positive mothers in Viet Nam: using their status to build support groups and access essential services , 2008, Reproductive health matters.

[38]  N. Ford,et al.  A systematic review of task- shifting for HIV treatment and care in Africa , 2010, Human resources for health.

[39]  M. Mckee,et al.  Health systems and increased longevity in people with HIV and AIDS , 2009, BMJ : British Medical Journal.

[40]  Sa Azin,et al.  An overview on the 2008 UNAIDS Report on the 2008 UNAIDS Report on the Global AIDS Epidemic. , 2010 .

[41]  D. Serwadda,et al.  The history and challenge of HIV prevention , 2008, The Lancet.

[42]  Tara S. Beattie,et al.  Declines in risk behaviour and sexually transmitted infection prevalence following a community-led HIV preventive intervention among female sex workers in Mysore, India , 2008, AIDS.

[43]  D. van Rensburg,et al.  Community health workers and the response to HIV/AIDS in South Africa: tensions and prospects. , 2008, Health policy and planning.

[44]  Ronald H Gray,et al.  HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy , 2011, AIDS.

[45]  Douglas K Owens,et al.  Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia , 2006, AIDS.

[46]  M. Eriksson,et al.  Social capital and the decline in HIV transmission – A case study in three villages in the Kagera region of Tanzania , 2010, SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance.

[47]  D. Westreich,et al.  Tuberculosis in Patients Receiving Antiretroviral Treatment: Incidence, Risk Factors, and Prevention Strategies , 2011, Journal of acquired immune deficiency syndromes.

[48]  Sonya S. Shin,et al.  How does directly observed therapy work? The mechanisms and impact of a comprehensive directly observed therapy intervention of highly active antiretroviral therapy in Peru. , 2011, Health & social care in the community.

[49]  J. Bryce,et al.  Evidence-based public health: moving beyond randomized trials. , 2004, American journal of public health.

[50]  S. Narayanan,et al.  The transition to harm reduction: understanding the role of non-governmental organisations in Malaysia. , 2011, The International journal on drug policy.

[51]  R. Atun,et al.  The Global Fund's leadership on harm reduction: 2002-2009. , 2010, The International journal on drug policy.

[52]  Sanjeev Sinha,et al.  Challenges Experienced by Rural Women in India Living With AIDS and Implications for the Delivery of HIV/AIDS Care , 2011, Health care for women international.

[53]  E. Schouten,et al.  Community health workers for ART in sub-Saharan Africa: learning from experience – capitalizing on new opportunities , 2009, Human resources for health.

[54]  T. Rhodes,et al.  Harm Reduction: Evidence, Impacts and Challenges , 2010 .

[55]  T. Hallett,et al.  A Surprising Prevention Success: Why Did the HIV Epidemic Decline in Zimbabwe? , 2011, PLoS medicine.

[56]  H. Ward,et al.  Congenital syphilis in the United Kingdom , 2006, Sexually Transmitted Infections.

[57]  Sandra I McCoy,et al.  Weighing the gold in the gold standard: challenges in HIV prevention research , 2010, AIDS.

[58]  Oliver Laeyendecker,et al.  Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial , 2007, The Lancet.

[59]  B. Schwartländer,et al.  Treatment 2.0: catalysing the next phase of scale-up , 2011, The Lancet.

[60]  B. Agan,et al.  Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study , 2010, AIDS research and therapy.

[61]  D. Elson,et al.  The Financial Requirements of Achieving Gender Equality and Women's Empowerment , 2006 .

[62]  L. Bollinger.  How can we calculate the “E” in “CEA”? , 2008, AIDS.

[63]  R. Zachariah,et al.  Task shifting for antiretroviral treatment delivery in sub-Saharan Africa: not a panacea , 2008, The Lancet.